The board of the directors (the "Board") of Grand Pharmaceutical Group Limited announced that based on the information currently available to the Company and the preliminary review by the management of the Company over the unaudited management accounts of the Group for the six months ended 30 June 2022, it is expected that for the six months ended 30 June 2022, if excluding the changes in fair value of investment in Telix Pharmaceuticals Limited (the "Telix"), the consolidated net profit attributable to owners of the Company increased by not less than 20% as compared with the same period of last year, due to further expansion in markets of the Group's core products; and after considering the loss from changes in fair value of investment in Telix due to the decrease of its share price, it is expected that the consolidated net profit attributable to owners of the Company recorded a decrease of approximately 35%-45% as compared to that of the six months ended 30 June 2021 (the unaudited consolidated net profit attributable to owners of the Company for the six months ended 30 June 2021 amounted to approximately HKD 1,202,543,000, in which including gain from changes in fair value of investment in Telix amounted to approximately HKD 294.79 million). As the date of this announcement, the share price of Telix has increased by more than 72% as compared with the share price as at 30 June 2022 and recovered to the share price higher than that as at 31 December 2021, and the impact to the Group is substantially decreased. Furthermore, management did not notify any obvious substantial adverse impact to the operation of the Group during the current period.